Detection and quantitation of HCV RNA using real-time PCR after automated sample processing

Area of Science:

• Virology
• Molecular Diagnostics
• Hepatology

Background:

• Hepatitis C virus (HCV) RNA loss early in treatment predicts therapy response.
• Real-time polymerase chain reaction (PCR) assays are crucial for quantifying HCV RNA.
• Automated extraction methods improve HCV RNA quantification.

Purpose of the Study:

• To evaluate the performance of the COBAS Ampliprep-COBAS Taqman 48 (CAP/CTM) real-time PCR assay.
• To compare the CAP/CTM assay with the COBAS Amplicor HCV Monitor v 2.0 (CAM) assay.
• To assess the clinical utility of the CAP/CTM system for HCV RNA quantification.

Main Methods:

• Performance analysis of the CAP/CTM real-time PCR assay.
• Comparison of CAP/CTM with the CAM assay using 118 clinical samples.
• Assessment of assay specificity, linearity, and variability (intra- and inter-assay).

Main Results:

• The CAP/CTM assay demonstrated 100% specificity.
• Linearity was maintained across a wide range of HCV RNA concentrations.
• High correlation (r = 0.89, P < 0.001) was observed between CAP/CTM and CAM results, with minimal mean difference (0.17 log IU/ml).
• Variations were low: intra-assay (0.3-3.3%) and inter-assay (1.5-6.7%).

Conclusions:

• The CAP/CTM system is a reliable and accurate tool for quantifying HCV RNA in clinical settings.
• The assay's performance is not influenced by HCV genotype or subtype.
• This automated real-time PCR assay is suitable for routine clinical practice in managing hepatitis C treatment.